skip to main content

    Updated Visitor Guidelines

 

MENU

 

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

Sexual side effects of cancer treatment often unaddressed with female patients

A new study, presented at the annual ASTRO meeting, finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.

ASTRO 2022 Annual Meeting will be held Oct. 23-26

Rogel Cancer Center faculty and trainees will lead 30 presentations, posters and moderated sessions at the American Society of Radiation Oncology annual meeting. This year’s meeting will be held in-person, virtually and on-demand.

Machine learning creates opportunity for personalizeed ovarian cancer therapy

Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors.

U-M to lead multi-site $12M grant to study rare type of sarcoma

An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle. The grant, worth $12.3 million, is through the NCI’s SPORE, or Specialized Program of Research Excellence, which funds collaborative, interdisciplinary translational cancer research.

Pages